US Patent

US9611283 — Methods for inhibiting cell proliferation in ALK-driven cancers

Method of Use · Assigned to Ariad Pharmaceuticals Inc · Expires 2034-04-10 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for treating patients with ALK-driven cancers that are resistant to certain treatments or have specific ALK mutations.

USPTO Abstract

The invention features a method for treating patients who have an ALK-driven cancer, which is, or has become, refractory to one or more of crizotinib, CH5424802 and ASP3026, or which bears an ALK mutation identified herein, by administering a compound of formula (I) to the patient. The invention also features methods, kits, and compositions for characterizing ALK-driven cancers to determine whether they express an ALK mutant.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2837 — Alunbrig
U-2837 — Alunbrig
U-2837 — Alunbrig

Patent Metadata

Patent number
US9611283
Jurisdiction
US
Classification
Method of Use
Expires
2034-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Ariad Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.